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TUBERCULOSIS MAY 
PRODUCE RESISTANCE 
TO OTHER DISEASES
By Rebecca Yates 
UM Information Services
MISSOULA, Mont.--
Attempts to eradicate tuberculosis (TB) have produced a startling theory--small amounts 
of the disease may be more beneficial than harmful to man.
"We're really excited about this," said Dr. Carl L. Larson, M.D., director of the 
Stella Duncan Memorial Institute and professor of microbiology at the University of Montana 
in Missoula.
He was referring to research at the institute in which 24 experimental rabbits in­
fected with the tubercle bacillus have been studied for resistance to fibromatosis, a 
disease marked by the presence of multiple benign tumors.
Dr. Larson and his associates have concluded that rabbits actually infected with 
tuberculosis or vaccinated with a live vaccine containing attenuated tubercle bacilli 
develop a tremendous resistance to the virus-produced, tumorous disease.
"If everyone were vaccinated with BCG," Dr. Larson speculated, "it might make them 
resistant to other diseases," possibly including cancer.
BCG, a vaccine named after French scientist Albert Calmette and surgeon Alphonse 
Guerin, introduces an active tubercle bacillus into the body, thus immunizing through 
infection. Since it is a "live" vaccine it is not widely used in the United States, 
although it is used in prevention programs in other countries, Dr. Larson indicated.
more
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Part of the work of the Stella Duncan Memorial Institute, established in 1947 for 
the study of allergic diseases, has been to find a "killed" vaccine, a discovery which 
was made in 1964, by Dr. Larson and Dr. Edgar Ribi of the Rocky Mountain Laboratory in 
Hamilton, Montana. Another important aspect of the scientists’ work at the institute 
has been development of better methods for diagnosis of tuberculosis.
Out of his research, Dr. Larson has developed the theory that controlled infections 
with tubercle bacilli may be a blessing in disguise.
Scientists, he said, are realizing more and more the dangers of tampering with the 
natural order and "when you get rid of tuberculosis, you may allow other things to take 
place," he added,"things" such as typhoid, influenza and tumorous diseases.
"In 1899," Dr. Larson related, "someone found that if you infected guinea pigs with 
tuberculosis and subsequently gave them typhoid fever, they had resistance to the typhoid 
bacillus.
"In 1913," he continued, "there was a great outbreak of plague in Manchuria. In­
vestigators noticed that very few people who died of the plague had tuberculosis. This 
was very strange since it was known that there was a lot of active tuberculosis in Manchuria
"Experiments in 1958 at the Pasteur Institute showed that if you gave mice tuberculosi 
and then the plague infection, the mice recovered from the plague. If you give animals 
BCG," Dr. Larson said, "they will resist lethal doses of organisms related to the plague 
bacilli."
Tuberculosis, or the BCG vaccine, also may immunize against influenza, the doctor 
speculated.
"In 1918," he explained, "there was a great epidemic of influenza in this country.
In tuberculosis sanitariums they hardly had any cases of influenza. You can also instill 
resistance to influenza in mice by giving the animals tuberculosis. Another recent 
discovery is that BCG bacilli also are effective in the treatment of leprosy."
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In the basement of the Health Sciences Building where the Stella Duncan Institute 
houses its experimental animals, Dr. Larson examined a rabbit with its back shaved to show 
the ugly, scab-like tumors of fibromatosis.
Moving to a neighboring cage, Dr. Larson took out another rabbit, this one infected 
with the same disease but also vaccinated with BCG. The inflammation of the tumors in the 
vaccinated rabbit was much less severe.
Across the hall, a sign on the door warns: "Danger. Tuberculosis. Keep Out."
Donning a mask, Dr. Larson entered the contaminated room and produced a tuberculous 
rabbit. The animal also was infected with fibromatosis but showed remarkably less 
evidence of the disease than either of the other two rabbits.
Asked if such experiments with virus-produced tumors might have any relation to 
cancer research, Dr. Larson replied, "Yes, we believe many tumors to be virus produced."
Dr. Larson and his associates also are working to perfect the killed vaccine they 
discovered some five years ago, capping a search that began in 1955 when Dr. Larson was 
working with Dr. Edgar Ribi at the Rocky Mountain Laboratory.
The vaccine is made from an extract of the cell walls of the tubercle bacillus and 
the breakthrough in its production came when Dr. Larson was visiting the Pasteur Institute 
in Paris for a year.
Dr. Larson and Dr. Ribi had been attempting to break up the cell walls of the tubercul 
organism in water but found this water disruption failed to produce an effective immunizing 
vaccine. Researchers in France were using oil in working with the bacilli, but for a 
completely different purpose.
Back from Paris, the American scientist attempted a breakup in oil. This was an 
effective but messy process, Dr. Larson related, and later "purely by accident we found out 
if you broke these organisms in water, dried the cell walls and then put a drop of oil on 
them you formed a sort of paste that was as good as the cell walls broken up in oil."
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Test results with the vaccine have been successful, Dr. Larson said. "We can produce 
a resistance in mice which is very good. Guinea pigs and rabbits are very susceptible to 
tuberculosis and the resistance in them is not as good,” he explained.
Rabbits now are being vaccinated at the institute, however, and their rate of 
recovery studied. Dr. Larson produced several lung samples of tuberculous rabbits, plus 
those vaccinated with both BCG and the cell-wall vaccine. The lungs showed that in several 
cases the results of the killed vaccine were as good or better than those in the BCG 
inoculated rabbits.
Dr. Larson believes the cell-wall vaccine is more effective than BCG and would be of 
special benefit in this country, where every year some 50,000 persons still are attacked 
by tuberculosis and some 10,000 die from the disease each year.
Dr. Larson also believes a protoplasm by-product of the cell-wall vaccine may be much 
more efficient in diagnosis of tuberculosis than the present substance is. The skin test 
now used, the scientist explained, is not specific since the substance, PPD (purified 
protein derivative), actually contains 18 different antigens, or antibody producing agents. 
Thus, a person showing a positive reaction to the TB test actually may be infected with 
organisms other than the tubercle bacillus.
Dr. Larson feels the cell-wall by-product is as good or better than PPD and a 
preparation with only one antigen can be produced from the cell-wall material. Instead of 
a general test, diagnosticians might be able to apply five or six tests and if one showed 
a positive reaction the specific infecting organism could be detected.
The doctor also believes his substance would be less expensive to produce since it 
takes only 10 days to prepare, compared with the several months it takes to make PPD.
The Stella Duncan Memorial Institute was founded through a bequest left by UM alumna 
Stella Duncan Johnston, who died of bronchial asthma in 1948.
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The work of the institute is carried on with the interest from that bequest plus 
continuing grants from the Department of Health, Education and Welfare which over the 
past six years have totaled approximately $500,000.
In addition, Dr. Larson received a National Institutes of Health (NIH) Career 
Research Award for his salary to do research on resistance to tuberculosis and related 
diseases. One of only some 35 persons in this country to receive one of these life-time 
awards, Dr. Larson was the last recipient before the program was canceled.
Dr. Larson was born in Butte, Montana in 1909. He received his medical degree from 
the University of Minnesota in 1939 and holds an honorary doctor of science degree from 
the University of Montana.
He began his career with the NIH in 1939 as assistant chief of the Laboratory of 
Infectious Diseases at Bethesda, Md., and directed the Rocky Mountain Laboratory from 
January 1950 to October 1961. He became director of the Stella Duncan Memorial Institute 
in October 1962.
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